| Literature DB >> 26277836 |
Adriana Aparecida Tahara Kemp1, Camila Ribas Delecrode2, Giovannna César da Silva2, Fabiana Martins3, Ana Cláudia Figueiredo Frizzo4, Ana Cláudia Vieira Cardoso4.
Abstract
INTRODUCTION: The literature indicates that neonatal hearing screening should be universal, so a description of programs that adopt this recommendation is relevant.Entities:
Keywords: Audiologia; Audiology; Hearing tests; Neonatal screening; Testes auditivos; Triagem neonatal
Mesh:
Year: 2015 PMID: 26277836 PMCID: PMC9449022 DOI: 10.1016/j.bjorl.2015.07.010
Source DB: PubMed Journal: Braz J Otorhinolaryngol ISSN: 1808-8686
Figure 1Flowchart. RFHL, risk factors for hearing loss; TEOAE, transient-evoked otoacoustic emissions; DPEOAE, distortion product-evoked otoacoustic emissions; A-ABEP, automated-auditory brainstem emission potential.
Description of gender and age of infants who attended screening.
| Characteristics | % | |
|---|---|---|
| Male | 337 | 52.2 |
| Female | 308 | 47.8 |
| 5–10 | 308 | 44.7 |
| 11–15 | 122 | 18.9 |
| 16–20 | 91 | 14.1 |
| 21–30 | 40 | 6.2 |
| 26–30 | 36 | 5.6 |
| ≥30 | 48 | 7.5 |
Perinatal characteristics of babies screened in the program.
| Characteristics | % | |
|---|---|---|
| Normal | 393 | 60.9 |
| Cesarean | 252 | 39.1 |
| ≤36 | 5 | 0.8 |
| 37–41 | 631 | 97.8 |
| ≥42 | 9 | 1.4 |
| <1500 | 0 | 0 |
| ≥1500 and <2500 | 20 | 3.1 |
| ≥2500 and <3000 | 145 | 22.5 |
| ≥3000 and <4000 | 457 | 70.8 |
| ≥4000 | 23 | 3.6 |
| <4 | 1 | 0.1 |
| 5–7 | 54 | 8.4 |
| 8–10 | 590 | 91.5 |
| ≤4 | 0 | 0 |
| 5–7 | 3 | 0.5 |
| 8–10 | 642 | 99.5 |
| Yes | 49 | 7.6 |
| No | 596 | 92.4 |
| Hyperbilirubinemia (phototherapy) | 27 | 55.1 |
| Family history of hearing loss | 14 | 28.6 |
| Intensive care unit time of stay | 4 | 8.1 |
| Ototoxic drug use for more than five days | 4 | 8.1 |
| Congenital infections (syphilis and toxoplasmosis) | 3 | 6.1 |
| Craniofacial anomalies | 1 | 2 |
| Presence of syndromes | 1 | 2 |
| Blood transfusion (Rh incompatibility) | 1 | 2 |
Gestational profile of mothers of babies screened in the program.
| Characteristics | % | |
|---|---|---|
| 13–20 | 201 | 32.8 |
| 21–25 | 180 | 27.9 |
| 26–30 | 141 | 21.9 |
| 31–35 | 81 | 12.5 |
| ≥36 | 32 | 4.9 |
| Yes | 177 | 27.5 |
| No | 468 | 72.5 |
| Urinary infection | 138 | 78 |
| Placental abruption | 17 | 9.6 |
| Hypertension | 5 | 2.9 |
| Diabetes | 2 | 1.1 |
| Thyroid | 3 | 1.7 |
| Depression | 2 | 1.1 |
| Anemia | 4 | 2.2 |
| Other | 6 | 3.4 |
| Yes | 9 | 1.4 |
| No | 636 | 98.6 |
| Yes | 68 | 10.5 |
| Not | 577 | 89.5 |
| Yes | 159 | 24.6 |
| No | 486 | 75.4 |
Correlation among variables studied with the results of transient evoked otoacoustic emissions.
| Variables | |||
|---|---|---|---|
| Gender | 645 | 0.063755 | 0.10573 |
| Infant age | 645 | −0.089318 | 0.023297 |
| Maternal age | 645 | 0.066639 | 0.090831 |
| Gestational time | 645 | 0.002615 | 0.947151 |
| Type of delivery | 645 | −0.049478 | 0.209505 |
| Complications during pregnancy | 645 | 0.019603 | 0.619235 |
| Smoking during pregnancy | 645 | −0.02007 | 0.610904 |
| Alcohol or drugs during pregnancy | 645 | −0.047922 | 0.224215 |
| Medication during pregnancy | 645 | −0.012547 | 0.750441 |
| Infant weight | 645 | 0.002036 | 0.958835 |
| Apgar 1 min | 645 | 0.033942 | 0.389459 |
| Apgar 5 min | 645 | 0.030352 | 0.441587 |
| Presence of risk indicator | 645 | −0.055109 | 0.162128 |
T-EOAE, transient-evoked otoacoustic emissions; p, significance level; r, correlation coefficient.
Statistically significant relationship.